碳酸氢钠治疗瑞士肾移植受者代谢性酸中毒:一项多中心、随机、单盲、安慰剂对照的3期试验
Preserve-Transplant研究为瑞士3家大学医院开展的多中心、随机、单盲、安慰剂对照3期试验,纳入移植超过1年、估算GFR 15–89 mL/min/1.73 m²、血清碳酸氢盐≤22 mmol/L且近6个月移植物功能稳定的成人肾移植受者242例,1:1随机至口服碳酸氢钠1.5–4.5 g/日或匹配安慰剂治疗2年。主要终点24个月估算GFR斜率在两组间无显著差异(Wilcoxon秩和检验p=0.51;Welch t检验p=0.97),平均差异0.032 mL/min/1.73 m²/年(95%CI -1.644至1.707)。碳酸氢钠有效纠正代谢性酸中毒(血清碳酸氢盐21.3 mmol/L升至23.0 mmol/L,血pH 7.37升至7.39),不良事件与严重不良事件两组相似。作者结论认为不应普遍推荐碳酸氢钠用于保护肾移植受者的估算GFR。
要点
- 成人肾移植受者(移植>1年、估算GFR 15–89 mL/min/1.73 m²、血清碳酸氢盐≤22 mmol/L)口服碳酸氢钠1.5–4.5 g/日治疗2年,估算GFR斜率与安慰剂无显著差异(p=0.51;p=0.97)。
- 估算GFR年斜率:安慰剂组中位数-0.722 mL/min/1.73 m²(IQR -4.081至1.440)、均值-1.862(SD 6.344);碳酸氢钠组中位数-1.413(IQR -4.503至1.139)、均值-1.830(SD 6.233)。
- 平均差异0.032 mL/min/1.73 m²/年(95%CI -1.644至1.707),亚组分析与敏感性分析均未显示显著差异。
- 碳酸氢钠有效纠正代谢性酸中毒:血清碳酸氢盐从21.3 mmol/L(SD 2.6)升至23.0 mmol/L(2.7),血pH从7.37(SD 0.06)升至7.39(0.04)。
- 不良事件与严重不良事件两组相似;安慰剂组1例(1%)死于SARS-CoV-2所致急性呼吸窘迫综合征、1例(1%)死于腹泻后严重脱水继发心脏骤停,碳酸氢钠组1例(1%)心脏性猝死。
适用人群与场景
- 成人(≥18岁)男性及女性长期肾移植受者,移植时间超过1年。
- 关键纳入标准:估算GFR 15 mL/min/1.73 m²至89 mL/min/1.73 m²,研究纳入前6个月内移植物功能稳定(血清肌酐变化<15%),血清碳酸氢盐≤22 mmol/L。
- 研究在瑞士3家大学医院(苏黎世、伯尔尼、日内瓦)开展。
诊断标准与关键阈值
- 代谢性酸中毒定义为血清碳酸氢盐≤22 mmol/L。
- 移植物功能稳定定义为研究纳入前6个月内血清肌酐变化<15%。
- 估算GFR入选范围为15 mL/min/1.73 m²至89 mL/min/1.73 m²。
处置流程与药物剂量
- 随机1:1分配至口服碳酸氢钠1.5–4.5 g/日或匹配安慰剂,疗程2年。
- 使用耐酸软明胶胶囊,每粒500 mg碳酸氢钠或匹配的500 mg安慰剂胶囊;初始剂量为体重<70 kg者500 mg每日三次,体重≥70 kg者1000 mg每日三次。
- 随机化按研究中心和性别分层,采用置换区组设计(可变区组大小2和4)以保证均衡分配。
研究设计与关键结果
- 多中心、随机、单盲、安慰剂对照3期试验;2017年6月12日至2019年7月10日评估1114例肾移植受者资格,排除872例,242例随机分组(安慰剂组122例[50%],碳酸氢钠组120例[50%]);二次排除2例后,240例纳入意向性治疗分析。
- 主要终点24个月治疗期估算GFR斜率:安慰剂组中位数-0.722 mL/min/1.73 m²/年(IQR -4.081至1.440)、均值-1.862 mL/min/1.73 m²/年(SD 6.344);碳酸氢钠组中位数-1.413 mL/min/1.73 m²/年(IQR -4.503至1.139)、均值-1.830 mL/min/1.73 m²/年(SD 6.233)(Wilcoxon秩和检验p=0.51;Welch t检验p=0.97)。
- 平均差异0.032 mL/min/1.73 m²/年(95%CI -1.644至1.707)。亚组分析未显示估算GFR斜率显著差异,敏感性分析证实主要分析结果。
- 碳酸氢钠有效纠正代谢性酸中毒:2年治疗期内血清碳酸氢盐从21.3 mmol/L(SD 2.6)升至23.0 mmol/L(2.7),血pH从7.37(SD 0.06)升至7.39(0.04)。
- 不良事件与严重不良事件两组相似;3例受试者死亡:安慰剂组1例(1%)死于SARS-CoV-2所致急性呼吸窘迫综合征,1例(1%)死于腹泻后严重脱水继发低血压、急性肾损伤和代谢性酸中毒后心脏骤停;碳酸氢钠组1例(1%)心脏性猝死。
证据类型、等级与局限
- 证据类型:多中心、随机、单盲、安慰剂对照3期试验。
- 主要疗效分析基于改良意向性治疗人群(所有随机分配且完成基线访视的参与者);安全性人群为至少接受一剂研究药物的所有参与者。
- 试验注册号:ClinicalTrials.gov,NCT03102996。
- 资助:Swiss National Science Foundation。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在成人肾移植受者中,碳酸氢钠治疗2年纠正代谢性酸中毒未影响估算GFR下降,因此不应普遍推荐碳酸氢钠用于保护合并代谢性酸中毒的慢性肾脏病肾移植受者的估算GFR(移植物功能的替代标志物)。
- 碳酸氢钠治疗可有效纠正代谢性酸中毒(血清碳酸氢盐和血pH升高),但本研究未显示其带来估算GFR斜率获益。
- 不良事件与严重不良事件在碳酸氢钠组与安慰剂组相似。
指南或共识出处
- Preserve-Transplant Study,发表于Lancet,注册号NCT03102996。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Metabolic acidosis is common in kidney transplant recipients and is associated with declining graft function. Sodium bicarbonate treatment effectively corrects metabolic acidosis, but no prospective studies have examined its effect on graft function. Therefore, we aimed to test whether sodium bicarbonate treatment would preserve graft function and slow the progression of estimated glomerular filtration rate (GFR) decline in kidney transplant recipients.
METHODS: The Preserve-Transplant Study was a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial at three University Hospitals in Switzerland (Zurich, Bern, and Geneva), which recruited adult (aged ≥18 years) male and female long-term kidney transplant recipients if they had undergone transplantation more than 1 year ago. Key inclusion criteria were an estimated GFR between 15 mL/min per 1·73 m2 and 89 mL/min per 1·73 m2, stable allograft function in the last 6 months before study inclusion (<15% change in serum creatinine), and a serum bicarbonate of 22 mmol/L or less. We randomly assigned patients (1:1) to either oral sodium bicarbonate 1·5-4·5 g per day or matching placebo using web-based data management software. Randomisation was stratified by study centre and gender using a permuted block design to guarantee balanced allocation. We did multi-block randomisation with variable block sizes of two and four. Treatment duration was 2 years. Acid-resistant soft gelatine capsules of 500 mg sodium bicarbonate or matching 500 mg placebo capsules were given at an initial dose of 500 mg (if bodyweight was <70 kg) or 1000 mg (if bodyweight was ≥70 kg) three times daily. The primary endpoint was the estimated GFR slope over the 24-month treatment phase. The primary efficacy analyses were applied to a modified intention-to-treat population that comprised all randomly assigned participants who had a baseline visit. The safety population comprised all participants who received at least one dose of study drug. The trial is registered with ClinicalTrials.gov, NCT03102996.
FINDINGS: Between June 12, 2017, and July 10, 2019, 1114 kidney transplant recipients with metabolic acidosis were assessed for trial eligibility. 872 patients were excluded and 242 were randomly assigned to the study groups (122 [50%] to the placebo group and 120 [50%] to the sodium bicarbonate group). After secondary exclusion of two patients, 240 patients were included in the intention-to-treat analysis. The calculated yearly estimated GFR slopes over the 2-year treatment period were a median -0·722 mL/min per 1·73 m2 (IQR -4·081 to 1·440) and mean -1·862 mL/min per 1·73 m2 (SD 6·344) per year in the placebo group versus median -1·413 mL/min per 1·73 m2 (IQR -4·503 to 1·139) and mean -1·830 mL/min per 1·73 m2 (SD 6·233) per year in the sodium bicarbonate group (Wilcoxon rank sum test p=0·51; Welch t-test p=0·97). The mean difference was 0·032 mL/min per 1·73 m2 per year (95% CI -1·644 to 1·707). There were no significant differences in estimated GFR slopes in a subgroup analysis and a sensitivity analysis confirmed the primary analysis. Although the estimated GFR slope did not show a significant difference between the treatment groups, treatment with sodium bicarbonate effectively corrected metabolic acidosis by increasing serum bicarbonate from 21·3 mmol/L (SD 2·6) to 23·0 mmol/L (2·7) and blood pH from 7·37 (SD 0·06) to 7·39 (0·04) over the 2-year treatment period. Adverse events and serious adverse events were similar in both groups. Three study participants died. In the placebo group, one (1%) patient died from acute respiratory distress syndrome due to SARS-CoV-2 and one (1%) from cardiac arrest after severe dehydration following diarrhoea with hypotension, acute kidney injury, and metabolic acidosis. In the sodium bicarbonate group, one (1%) patient had sudden cardiac death.
INTERPRETATION: In adult kidney transplant recipients, correction of metabolic acidosis by treatment with sodium bicarbonate over 2 years did not affect the decline in estimated GFR. Thus, treatment with sodium bicarbonate should not be generally recommended to preserve estimated GFR (a surrogate marker for graft function) in kidney transplant recipients with chronic kidney disease who have metabolic acidosis.
FUNDING: Swiss National Science Foundation.
参考来源
- Mohebbi N, Ritter A, Wiegand A, et al. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial. Lancet. 2023. PMID: 36708734. doi:10.1016/S0140-6736(22)02606-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。